Showing results (1-10 of 21) with videos related to
Sort By:
Pageof 3
Chemmedchem|April 1, 2018
Niclosamide, a Drug with Many (Re)purposesHachemi Kadri, Olivia A Lambourne, Youcef MehellouMini Reviews in Medicinal Chemistry|June 10, 2008
The development of pro-apoptotic cancer therapeuticsNoha I Ziedan, Hachemi Kadri, Andrew D WestwellJournal of Medicinal Chemistry|August 26, 2016
Nucleoside Phosphate and Phosphonate Prodrug Clinical CandidatesPeter J Thornton, Hachemi Kadri, Ageo Miccoli, et al.Pharmaceutics|May 27, 2026
From Solid Dispersions to Enzyme-Responsive Nanocarriers: Whey Protein Isolate Nanoparticles for Enhanced Curcumin Encapsulation and Targeted DeliveryMarwa Megahed, Jaina Patel, Mohammad Najlah, et al.Biochemical and Biophysical Research Communications|August 1, 2018
C-terminal phosphorylation of SPAK and OSR1 kinases promotes their binding and activation by the scaffolding protein MO25Youcef Mehellou, Mubarak A Alamri, Binar A Dhiani, et al.Bioorganic & Medicinal Chemistry Letters|April 2, 2013
Synthesis and antioxidant properties of substituted 2-phenyl-1H-indolesCigdem Karaaslan, Hachemi Kadri, Tulay Coban, et al.Molecules (Basel, Switzerland)|November 27, 2024
Nucleoside Analogues for Chagas Disease and Leishmaniasis Therapy: Current Status and Future PerspectivesEmmanuel Awucha Nwoke, Silvester Lowe, Fawaz Aldabbagh, et al.Chembiochem : a European Journal of Chemical Biology|July 13, 2018
The Photosensitising Clinical Agent Verteporfin Is an Inhibitor of SPAK and OSR1 KinasesMubarak A AlAmri, Hachemi Kadri, Luke J Alderwick, et al.Chemmedchem|April 4, 2017
Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their C-terminal DomainsMubarak A AlAmri, Hachemi Kadri, Luke J Alderwick, et al.Pharmaceutics|October 29, 2025
Albumin Nanoparticles in Cancer Therapeutics: Clinical Status, Challenges, and Future DirectionsHachemi Kadri, Mesk Alshatfa, Feras Z Alsalloum, et al.Pageof 3